

May 1, 2020



Trevena to Release First Quarter 2020 Financial Results on May 7, 2020

Company to host conference call on May 7, 2020, at 8:00 a.m. ET

CHESTERBROOK, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- **Trevena, Inc. (Nasdaq: TRVN)**, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2020, prior to the market open on Thursday, May 7, 2020.

Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. (ET) on the same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Bob Yoder, SVP and Chief Business Officer, Mark Demitrack, SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Officer.

Title: Trevena First Quarter 2020 Financial Results Conference Call & Webcast

Date: Thursday, May 7, 2020

Time: 8:00 a.m. ET

Conference Toll-Free: 855-465-0180
International: 484-756-4313
Call Details: Conference ID: 5469527

The conference call will be webcast live from the company's website and will be available via the following links:

<https://www.trevena.com/investors/events-presentations/ir-calendar>

Webcast:

<https://edge.media-server.com/mmc/p/r7x9zckv>

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the company's website.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has

four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

For more information, please contact:

Investor Contact:

Dan Ferry - Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576

Company Contact:

Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840



Source: Trevena Inc.